23 Feb 2026·Source: The Hindu

4 min

Science & TechnologyNEWS

Biotechnology to Drive Personalized Medicine Evolution: Experts

Experts say biotechnology is set to drive evolution of personalised medicine.

India's biotechnology sector is set to receive a massive boost with a ₹10,000 crore investment outlined in the Union Budget 2026-27, positioning the nation as a global biopharma manufacturing hub. This investment aims to significantly increase the production of biologics and biosimilars through the Biopharma Shakti initiative. The focus is on shifting medical treatments from a reactive approach to a proactive and personalized model, tailoring treatments based on individual genetic, metabolic, lifestyle, seasonal, regional, and ethnic profiles.

Biotechnology education is also evolving to integrate genomics, bioinformatics, data science, and clinical practice, preparing professionals for this new era of personalized medicine. VIT, Chennai, will launch a new biotechnology program in 2027 to further support this educational transformation.

Key Facts

India is poised to become a global biopharma manufacturing hub.

The Union Budget 2026-27 includes a massive investment of ₹10,000 crore in the biotechnology sector.

The Biopharma Shakti initiative aims to boost the production of biologics and biosimilars.

Medical treatments are undergoing a paradigm shift from reactive to proactive and standardized to individualized treatments.

Biotechnology education is integrating genomics, bioinformatics, data science, and clinical practice.

UPSC Exam Angles

GS Paper III: Science and Technology - Developments and their applications and effects in everyday life

GS Paper II: Government policies and interventions for development in various sectors and issues arising out of their design and implementation

Potential questions on government schemes, biotechnology advancements, and ethical considerations in healthcare

In Simple Words

Personalized medicine means treatments are tailored to you. Instead of giving everyone the same medicine, doctors will use your genes and lifestyle to choose the best treatment. It's like getting a custom-made plan just for your health.

India Angle

In India, this could mean better treatments for diseases common here, like diabetes or heart problems. Doctors can use genetic information to prescribe the right medicine and lifestyle changes for each person. This could improve health outcomes and reduce healthcare costs.

For Instance

Think of it like buying a phone. Some people want a basic phone, while others want a smartphone with all the features. Personalized medicine is like getting the phone that best fits your needs and preferences.

Personalized medicine can lead to more effective treatments with fewer side effects. It can also help prevent diseases by identifying risks early on.

Personalized medicine: Your health, your genes, your treatment.

Experts at a webinar stated that India is poised to become a global biopharma manufacturing hub with a massive investment of ₹10,000 crore in the biotechnology sector in the Union Budget 2026-27. The focus is on boosting the production of biologics and biosimilars through the Biopharma Shakti initiative. Medical treatments are undergoing a paradigm shift from reactive to proactive and standardized to individualized treatments based on genetic, metabolic, lifestyle, season, region, and ethnic profiles.

Biotechnology education is evolving and integrating genomics, bioinformatics, data science, and clinical practice to prepare professionals for personalized medicine. A new biotechnology program will be launched at VIT, Chennai in 2027.

Expert Analysis

The future of medicine is increasingly intertwined with biotechnology, moving towards personalized treatments tailored to individual needs. Several key concepts underpin this shift.

The Biopharma Shakti Initiative is a government program designed to boost the production of biologics and biosimilars in India. With a ₹10,000 crore investment in the biotechnology sector outlined in the Union Budget 2026-27, this initiative aims to establish India as a global biopharma manufacturing hub. This initiative directly supports the shift towards personalized medicine by increasing the availability and affordability of advanced treatments.

Personalized medicine is an approach to healthcare that tailors medical treatment to the individual characteristics of each patient. This contrasts with a "one-size-fits-all" approach, where treatments are standardized for the general population. Personalized medicine utilizes information about a person's genetic makeup, metabolic profile, lifestyle, and environmental factors to customize prevention, diagnosis, and treatment strategies. The integration of genomics, bioinformatics, and data science is crucial for advancing personalized medicine, as highlighted by the evolving biotechnology education programs.

Genomics is the study of an organism's complete set of DNA, including its genes. Advances in genomics have enabled researchers to identify genetic variations that influence an individual's susceptibility to diseases and their response to treatments. This information is essential for personalized medicine, as it allows healthcare providers to tailor treatments based on a patient's unique genetic profile. The integration of genomics into biotechnology education, as seen with the new program at VIT, Chennai, is crucial for preparing professionals for the future of healthcare.

Bioinformatics is an interdisciplinary field that develops methods and software tools for understanding biological data. It combines computer science, statistics, mathematics, and engineering to analyze and interpret large datasets generated from genomics, proteomics, and other biological research. In the context of personalized medicine, bioinformatics plays a crucial role in analyzing genomic data to identify potential drug targets and predict treatment outcomes. The integration of bioinformatics into biotechnology education is essential for training professionals who can effectively utilize these tools to advance personalized medicine.

For UPSC aspirants, understanding the convergence of biotechnology and personalized medicine is crucial. Prelims questions may focus on government initiatives like the Biopharma Shakti Initiative, key concepts such as genomics and bioinformatics, and their applications in healthcare. Mains questions may explore the ethical, social, and economic implications of personalized medicine, as well as the role of government policies in promoting its development and accessibility.

Visual Insights

Key Statistics from Biotechnology Sector

Highlights the investment and focus areas in the biotechnology sector as per the news article.

Biotechnology Sector Investment: ₹10,000 crore

More Information

Background

The biotechnology sector in India has been steadily growing, driven by increasing investments in research and development, a supportive regulatory environment, and a growing demand for biopharmaceuticals. The National Biotechnology Development Strategy, launched by the Department of Biotechnology, aims to promote innovation, entrepreneurship, and infrastructure development in the sector. This strategy has played a crucial role in attracting investments and fostering collaborations between academia and industry. Recent years have witnessed significant advancements in genomics, bioinformatics, and personalized medicine, transforming the landscape of healthcare. The development of high-throughput sequencing technologies and sophisticated data analysis tools has enabled researchers to identify genetic markers for various diseases and develop targeted therapies. The Biopharma Shakti Initiative is a direct response to these advancements, aiming to leverage India's manufacturing capabilities to produce affordable and accessible biopharmaceuticals. The integration of biotechnology into education is essential for preparing the next generation of scientists and healthcare professionals. Universities and research institutions are increasingly incorporating genomics, bioinformatics, and data science into their curricula. The launch of a new biotechnology program at VIT, Chennai, is a testament to this trend, reflecting the growing demand for skilled professionals in the field.

Latest Developments

In recent years, there has been a growing emphasis on precision medicine and personalized healthcare solutions. The government has launched several initiatives to promote research and development in this area, including funding for multi-omics studies and the establishment of centers of excellence for genomics and bioinformatics. These efforts aim to accelerate the translation of research findings into clinical practice.

The pharmaceutical industry is increasingly adopting advanced technologies such as artificial intelligence and machine learning to accelerate drug discovery and development. AI-powered tools are being used to analyze large datasets, identify potential drug targets, and predict treatment outcomes. This is expected to significantly reduce the time and cost associated with bringing new drugs to market.

Looking ahead, the focus will be on ensuring equitable access to personalized medicine and addressing the ethical and regulatory challenges associated with these technologies. This includes developing guidelines for data privacy, algorithmic bias, and the responsible use of genetic information. The success of personalized medicine will depend on collaboration between researchers, healthcare providers, policymakers, and the public.

Frequently Asked Questions

1. What's the difference between 'biologics' and 'biosimilars' that the Biopharma Shakti initiative aims to boost?

Biologics are drugs derived from living organisms (like cells or tissues), often complex and expensive to produce. Biosimilars are 'generic' versions of biologics, similar but not identical due to the complexities of biological manufacturing. They offer a more affordable alternative once the patent on the original biologic expires.

Exam Tip

Remember: 'BioSIMILAR' means 'similar to' an existing biologic drug, not a completely new drug. UPSC might trick you with options suggesting they are novel molecules.

2. The article mentions a ₹10,000 crore investment in biotech by 2026-27. What specific areas are likely to receive the most funding, and why?

Given the focus on personalized medicine and biopharma manufacturing, the largest share of the ₹10,000 crore investment will likely go towards: * Biologics and Biosimilars Manufacturing: Expanding production capacity under the Biopharma Shakti initiative. * Genomics and Bioinformatics Research: Supporting multi-omics studies and centers of excellence. * Biotechnology Education and Skill Development: Funding programs that integrate genomics, data science, and clinical practice, like the new program at VIT Chennai.

Exam Tip

Prelims Tip: Note the specific amount (₹10,000 crore) and the initiative (Biopharma Shakti). UPSC loves to test specific numbers related to government schemes.

3. How does this push for personalized medicine align with the National Biotechnology Development Strategy, and what challenges might hinder its success?

The push for personalized medicine directly supports the National Biotechnology Development Strategy's goals of promoting innovation and R&D in the biotech sector. It aims to translate research into practical healthcare solutions. However, challenges include: * High Costs: Personalized treatments can be expensive, limiting accessibility. * Data Privacy Concerns: Handling sensitive genetic and medical data requires robust privacy safeguards. * Regulatory Hurdles: Clear regulatory pathways are needed for personalized medicine products.

Exam Tip

For Mains, remember the ethical considerations (data privacy) and economic factors (cost) when discussing personalized medicine. A balanced answer is key.

4. What are the potential ethical concerns surrounding personalized medicine, especially regarding data privacy and equitable access?

Personalized medicine raises significant ethical concerns: * Data Privacy: Genetic information is highly sensitive. Breaches could lead to discrimination in insurance or employment. * Equitable Access: Personalized treatments may be too expensive for many, exacerbating healthcare disparities. * Informed Consent: Patients need to fully understand the implications of genetic testing and personalized treatments. * Genetic Discrimination: Laws may be needed to prevent discrimination based on genetic predispositions.

Exam Tip

When discussing ethics, always consider multiple stakeholders: patients, healthcare providers, researchers, and the government. Show awareness of different perspectives.

5. How might the integration of genomics, bioinformatics, and data science into biotechnology education impact India's healthcare sector in the long run?

Integrating these fields will create a workforce capable of: * Developing Targeted Therapies: Designing treatments based on individual genetic profiles. * Improving Disease Diagnosis: Using data analysis to identify disease patterns and predict risks. * Enhancing Drug Discovery: Accelerating the development of new drugs and therapies. * Promoting Preventive Healthcare: Identifying individuals at risk for certain diseases and implementing preventive measures.

Exam Tip

Think long-term! UPSC often asks about the 'potential' or 'future implications' of a technology. Focus on the transformative possibilities.

6. What is 'Industry 5.0', mentioned in the background, and how does it relate to the advancements in personalized medicine being discussed?

Industry 5.0 refers to the next phase of industrial revolution, characterized by collaboration between humans and machines, personalization, and sustainability. In the context of personalized medicine: * Personalization: Industry 5.0 emphasizes customized solutions, aligning with the core principle of tailoring treatments to individual needs. * Human-Machine Collaboration: AI and data analytics (machines) assist doctors (humans) in making more informed treatment decisions. * Advanced Manufacturing: Technologies like 3D printing enable the creation of personalized medical devices and implants.

Exam Tip

Don't just define Industry 5.0. Connect it to the specific context of the news (personalized medicine). This shows analytical ability, which UPSC values.

Practice Questions (MCQs)

1. Consider the following statements regarding the Biopharma Shakti Initiative: 1. It aims to boost the production of biologics and biosimilars in India. 2. It is funded with a ₹10,000 crore investment outlined in the Union Budget 2026-27. 3. It focuses on standardizing medical treatments for the general population. Which of the statements given above is/are correct?

A.1 and 2 only
B.2 and 3 only
C.1 and 3 only
D.1, 2 and 3

Show Answer

Answer: A

Statements 1 and 2 are correct. The Biopharma Shakti Initiative aims to boost the production of biologics and biosimilars in India with a ₹10,000 crore investment outlined in the Union Budget 2026-27. Statement 3 is incorrect because the initiative focuses on personalized medicine, tailoring treatments based on individual profiles, not standardizing them for the general population.

2. In the context of personalized medicine, which of the following factors are considered for tailoring treatments to individual patients? 1. Genetic makeup 2. Metabolic profile 3. Lifestyle 4. Regional and ethnic profiles Select the correct answer using the code given below:

A.1 and 2 only
B.2 and 3 only
C.1, 2 and 3 only
D.1, 2, 3 and 4

Show Answer

Answer: D

All the factors listed are considered in personalized medicine. Treatments are tailored based on individual genetic makeup, metabolic profile, lifestyle, and regional and ethnic profiles to provide the most effective and targeted care.

3. Which of the following statements best describes the role of bioinformatics in advancing personalized medicine? A) It focuses solely on the ethical considerations of genetic testing. B) It develops methods and software tools for understanding biological data. C) It primarily deals with the manufacturing of biopharmaceuticals. D) It is limited to the study of plant genomes.